EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Use of canakinumab and remdesivir in moderate-severe COVID-19 patients: A retrospective analysis

Antonio Mastroianni iD, Valeria Vangeli, Luciana Chidichimo, Filippo Urso, Giuseppe De Marco, Alfredo Zanolini, Francesca Greco, Maria V Mauro, Sonia Greco

International Journal of Immunopathology and Pharmacology · 2023

DOI: 10.1177/03946320231189993 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Immunopathology and Pharmacology, 2023. Verfasst von Antonio Mastroianni und 8 weiteren Autor:innen. Beteiligte Einrichtung: Infectious & Tropical Diseases Unit, "Annunziata" Hospital, Azienda Ospedaliera di Cosenza, Cosenza, Italy. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The dysregulated immune response occurring upon COVID-19 infection can lead to tissue damage and organ failure. Different therapeutic strategies are needed to cope with the current and future outspread of COVID-19, including antiviral and anti-inflammatory agents. We describe the outcome of hospitalized patients treated with canakinumab and remdesivir plus the standard of care therapy.

Methods

This observational study describes the outcome of the combination of canakinumab (450 mg for patients ≥40 and

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansAdultMiddle AgedAgedAged, 80 and overSARS-CoV-2Retrospective StudiesTreatment OutcomeCOVID-19 Drug TreatmentAntiviral AgentsAntibodies, Monoclonal, HumanizedAdenosine MonophosphateAlanine

Stichwörter der Autor:innen

COVID-19canakinumabhematological markersinflammatory markersremdesivir

Substanzen

Antiviral AgentscanakinumabAntibodies, Monoclonal, HumanizedremdesivirAdenosine MonophosphateAlanine

Autor:innen und Institutionen

  • Infectious & Tropical Diseases Unit, "Annunziata" Hospital, Azienda Ospedaliera di Cosenza, Cosenza, Italy.
  • Hospital Pharmacy, "Annunziata" Hospital, Azienda Ospedaliera di Cosenza, Cosenza, Italy.
  • Radiology Unit, "Annunziata" Hospital, Azienda Ospedaliera di Cosenza, Cosenza, Italy.
  • Microbiology & Virology Unit, "Annunziata" Hospital, Azienda Ospedaliera di Cosenza, Cosenza, Italy.

ORCID-Profile: Antonio Mastroianni

Zitieren

APA

Mastroianni, A., Vangeli, V., Chidichimo, L., Urso, F., De Marco, G., Zanolini, A., Greco, F., Mauro, M. V., & Greco, S. (2023). Use of canakinumab and remdesivir in moderate-severe COVID-19 patients: A retrospective analysis. International Journal of Immunopathology and Pharmacology. https://doi.org/10.1177/03946320231189993

Vancouver

Mastroianni A, Vangeli V, Chidichimo L, Urso F, De Marco G, Zanolini A, et al. Use of canakinumab and remdesivir in moderate-severe COVID-19 patients: A retrospective analysis. International Journal of Immunopathology and Pharmacology. 2023. doi:10.1177/03946320231189993

BibTeX
@article{Mastroianni2023,
  author = {Mastroianni, Antonio and Vangeli, Valeria and Chidichimo, Luciana and Urso, Filippo and De Marco, Giuseppe and Zanolini, Alfredo and Greco, Francesca and Mauro, Maria V and Greco, Sonia},
  title = {Use of canakinumab and remdesivir in moderate-severe COVID-19 patients: A retrospective analysis},
  journal = {International Journal of Immunopathology and Pharmacology},
  year = {2023},
  doi = {10.1177/03946320231189993}
}
Kostenlos starten →